The outcomes and prognostic factors in patients after reoperation of persistent/recurrent papillary thyroid carcinoma
crossref(2022)
摘要
Abstract Background: The most suitable approach for the treatment of recurrent papillary thyroid carcinoma (PTC) remains controversial and reoperation may be an effective method. The efficacy of reoperation in these patients with locoregional recurrence, especially the ones with unsatisfying efficacy of radioactive iodine ablation, is still uncertain. This study aimed to clarify clinical management strategies for locoregional recurrence of PTC and to explore factors that may affect long-term patient outcomes after reoperation.Methods: In total, 124 patients who initially underwent thyroidectomy and variable extents of RAI therapy and finally received reoperation for locoregionally recurrent PTC, were included. Parameters associated with recurrence-free survival (RFS) were analyzed using a Cox proportional hazards model.Results: Thirty-two patients had secondary clinical recurrence after reoperation during follow-up. Metastatic lymph nodes with extra-nodal extension (P=0.023) and high post-reoperative (post-reop) unstimulated thyroglobulin (unstim-Tg) levels (P=0.001) were independent prognostic factors for recurrence-free survival. Neither the avidity of RAI nor the frequency and dose of RAI therapies before reoperation affected long-term outcome.Conclusions: Patients with locoregionally recurrent PTC rarely benefit from additional RAI therapy before reoperation, and surgical intervention should be prioritized in the clinical management of locoregionally recurrent PTC. Metastatic lymph nodes with extra-nodal extension and post-reop unstim-Tg >10.1 ng/mL may have a poor prognosis.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn